Dual inhibition of SUMOylation and MEK conquers MYC-expressing KRAS-mutant cancers by accumulating DNA damage
Abstract Background KRAS mutations frequently occur in cancers, particularly pancreatic ductal adenocarcinoma, colorectal cancer, and non-small cell lung cancer. Although KRAS G12C inhibitors have recently been approved, effective precision therapies have not yet been established for all KRAS-mutant...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BMC
2024-07-01
|
| Seri Bilgileri: | Journal of Biomedical Science |
| Konular: | |
| Online Erişim: | https://doi.org/10.1186/s12929-024-01060-3 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|